Hansa Biopharma
Develops immunomodulating therapies for rare autoimmune conditions, transplant rejection and cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $25.0m | Post IPO Equity | |
| Total Funding | 000k | ||
| SEK | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 456 % | 356 % | (13 %) | 28 % | 60 % | 90 % | 96 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (1589 %) | (355 %) | (526 %) | (360 %) | (154 %) | (58 %) | (16 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1618 %) | (395 %) | (620 %) | (471 %) | (167 %) | (63 %) | 5 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 681 % | 224 % | 307 % | 219 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Hansa Biopharma is a biopharmaceutical company focused on developing innovative immunomodulatory treatments. The company primarily serves patients with unmet medical needs, particularly those who are highly sensitized and require kidney transplants. Operating in the biotechnology and healthcare market, Hansa Biopharma leverages its proprietary antibody cleaving enzyme technology platform to target pathogenic antibodies, which are harmful proteins in the body that can cause diseases. The business model revolves around research and development, clinical trials, and the commercialization of its treatments. Revenue is generated through the sale of its approved therapies and potential licensing agreements with other pharmaceutical companies. Hansa Biopharma's strong company culture has earned it recognition as a Great Place to Work for four consecutive years from 2020 to 2023. The company is also listed among the best workplaces in Sweden in 2023.
Keywords: immunomodulatory, antibody cleaving enzyme, kidney transplant, biotechnology, healthcare, unmet medical needs, clinical trials, commercialization, licensing, Sweden.